{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-082819","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2025-04-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.589904+00:00","generated_at":"2026-05-23T13:30:39.691444+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Kalaris Therapeutics enters new CEO employment agreement with severance benefits; CAO severance set","bullets":["CEO Oxtoby's new base salary is $569,100; target bonus up to 55% of base salary.","On non-CIC termination without cause/good reason: 12 months base salary plus COBRA.","On CIC termination: 18 months base salary, 150% target bonus lump sum, 18 months COBRA, full equity acceleration.","CAO Hagen gets 9 months base salary (non-CIC) or 12 months plus 100% target bonus lump sum (CIC) and equity acceleration.","Both agreements require release and continued compliance with restrictive covenants."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-082819","json":"https://secwatch.observer/filing/0001193125-25-082819.json","markdown":"https://secwatch.observer/filing/0001193125-25-082819.md","text":"https://secwatch.observer/filing/0001193125-25-082819.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312525082819/0001193125-25-082819-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312525082819/d949516d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T13:30:39.691444+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}